The Oncology Institute
About: The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services.
Employees: 800
0
Funds holding %
of 7,139 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
200% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 3
7.8% less ownership
Funds ownership: 27.27% [Q3] → 19.47% (-7.8%) [Q4]
9% less funds holding
Funds holding: 34 [Q3] → 31 (-3) [Q4]
34% less capital invested
Capital invested by funds: $6.98M [Q3] → $4.61M (-$2.37M) [Q4]
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Research analyst outlook
We haven’t received any recent analyst ratings for TOI.
Financial journalist opinion
Neutral
GlobeNewsWire
2 months ago
Florida Blue enhances cancer care for thousands of members
New program aims to improve patient outcomes, experience, and quality of life by streamlining access to affordable and high-quality oncology care New program aims to improve patient outcomes, experience, and quality of life by streamlining access to affordable and high-quality oncology care
Neutral
GlobeNewsWire
3 months ago
Grapevine Saves The Oncology Institute Millions On Healthcare Supplies
Proof that Digital Transformation and Smarter Supply Chains Can Massively Cut Costs Proof that Digital Transformation and Smarter Supply Chains Can Massively Cut Costs
Neutral
Seeking Alpha
3 months ago
The Oncology Institute, Inc. (TOI) Q3 2024 Earnings Call Transcript
The Oncology Institute, Inc. (NASDAQ:TOI ) Q3 2024 Earnings Conference Call November 13, 2024 5:00 PM ET Company Participants Mark Hueppelsheuser - General Counsel Daniel Virnich - CEO Rob Carter - CFO Operator Good afternoon and welcome to The Oncology Institute's Third Quarter 2024 Earnings Conference Call. Today's call is being recorded, and we have allocated one hour for prepared remarks and Q&A.
Neutral
Accesswire
3 months ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into The Oncology Institute, Inc.
NEW YORK, NY / ACCESSWIRE / November 8, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November 9, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as DFP Healthcare Acquisitions Corp. (DFPH), and whether the Board of TOI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
Neutral
Accesswire
3 months ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into The Oncology Institute, Inc.
NEW YORK, NY / ACCESSWIRE / November 7, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November 9, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as DFP Healthcare Acquisitions Corp. (DFPH), and whether the Board of TOI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
Neutral
Accesswire
3 months ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into The Oncology
NEW YORK, NY / ACCESSWIRE / November 6, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November 9, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as DFP Healthcare Acquisitions Corp. (DFPH), and whether the Board of TOI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
Neutral
Accesswire
3 months ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into The Oncology Institute, Inc.
NEW YORK, NY / ACCESSWIRE / November 5, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November 9, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as DFP Healthcare Acquisitions Corp. (DFPH), and whether the Board of TOI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
Neutral
GlobeNewsWire
3 months ago
The Oncology Institute Announces Third Quarter 2024 Earnings Release Date and Conference Call
CERRITOS, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its third quarter 2024 financial results after the market close on Wednesday, November 13, 2024, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time).
Neutral
Accesswire
3 months ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into The Oncology
NEW YORK, NY / ACCESSWIRE / November 4, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November 9, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as DFP Healthcare Acquisitions Corp. (DFPH), and whether the Board of TOI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
Neutral
Accesswire
3 months ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into The Oncology Institute, Inc.
NEW YORK, NY / ACCESSWIRE / November 1, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November 9, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as DFP Healthcare Acquisitions Corp. (DFPH), and whether the Board of TOI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
Charts implemented using Lightweight Charts™